AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Cessation 25 Aug - Ganesh Potdar resigned as Whole-Time Director effective 25 Aug 2026.
Source: Bse
Lasa Supergenerics Limited (LASA)
Small CapPharma stocks · Small cap · NSE
Lasa Supergenerics Limited operates in API, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:50 pm ISTDetails
Quote21 Oct, 03:50 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:11 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage11/14 · 79%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
53Neutralfull bear SMA stack · SMA20 -11.0% / mo · RSI oversold · MACD − · near 52W low · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 22
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
LASAD candles · FIT view-38.6%TODAY · PROVISIONALLatest price ₹4.91 on 2026-10-21
Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.
Bar
-4.8%
RSI
13
MACD hist
-0.18
52W pos
0%
2026-10-21O ₹5.16H ₹5.39L ₹4.91C ₹4.91Vol 37,588 shIntraday candle
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
LASANifty PharmaNifty 500
- LASA
- -31.1%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -25.6 pp
Chart stats
19 Oct 2026- From 52W high
- -65.1%
- 52W range position
- 0%
- ATR (14)
- 8.1%
- Volume vs 20D
- 0.93x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹4.9 - ₹7.5
₹14.1
₹4.9 - ₹14.1
₹0.4
Latest completed session
20-session average
38.4% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED5
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue -93.8% · PAT NDF YoY
Technical
Neutral53
Price trend and sector-relative-strength timing.
Valuation
Legacy model—
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence53
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100Rev -94% YoY · margin compression
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1.2 Cr | -93.8% | NDF |
| EBITDA | ₹-1.4 Cr | -178.0% | +34.4% |
| Operating margin | -113.0% | -11051 bps | NDF |
| PAT | ₹-3.6 Cr | NDF | NDF |
| PAT margin | -291.1% | -18551 bps | NDF |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- —
- P/B
- 0.54
- EV/EBITDA
- —
- Market Cap
- 26.30Cr
Profitability
- ROE
- -19.70%
- ROCE
- -18.20%
- ROA
- -25.37%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -34.00%
- EPS 5Y
- -41.00%
- Revenue 3Y
- -42.00%
- EPS 3Y
- 10.00%
Balance Sheet
- Debt/Equity
- 0.20
- Interest Coverage
- —
- Altman Z
- 0.89
- Book Value
- 9.90
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 6/5
- OCF
- -8.00 Cr
- EPS TTM
- -3.30
Shareholding
- Promoter Hold
- 53.65%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 0%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 1.2+1046.2% vs prev
Net Profit
₹ CrLatest: -3.6+13.9% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 13.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~14.5% over last month) — short-term momentum negative.
- RSI(14) at 13 — oversold zone; bounce conditions.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
6
RS percentile
Stage 4 Downtrend
1M return
-29.8%
3M return
-33.6%
6M return
-23.5%
1Y return
-57.4%
RS 1D
0
RS 20D
-22
Sector rank
#1
Industry rank
#9
Stage evidence
- Price is 33.6% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -4.2%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
241 observations
19 Oct 2026Value 43.97-5.79%
RS vs Nifty 50044
Valuation & peers
U-Score 5 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 5 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Distress Watch
Fundamental score breakdown
U band · OVERVALUEDValuation5/30
Growth0/25
Quality0/20
Balance Sheet5/15
Cash Flow3/10
Piotroski
2/9 (+0)
Penalties
-8
Raw sum
5
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
5/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 5/15 to the score.
- Cash flow contributes 3/10 to the score.
- Valuation contributes 5/30 to the score.
Main drags
- Altman Z is 0.9, in distress territory.
- Penalty bucket subtracts 8 points.
- Growth is weaker at 0/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
0.5
EV/EBITDA
—
ROE
-19.7%
ROCE
-18.2%
FCF Yield
—
Debt/Equity
0.2
MoS
—
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
5
Previous: 5
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
—
No stored baseline yet
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
5
5
5
5
5
5
5
5
5
5
5
5
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
1.1
Growth-justified Value
—
— MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
MEDIORG
SME
Medicamen Organics Ltd.
Pharmaceuticals
match 156
14
—
-13.8%
—
OVERVALUED
SAROJA
SME
Saroja Pharma Industries India Ltd.
Pharmaceuticals
match 155
48
9.8
10.1%
+77%
FAIR VALUE
ARVEE
Small
Arvee Laboratories (India) Limited
Pharmaceuticals
match 149
16
57.0
7.3%
-736%
OVERVALUED
GUJTHEM
Small
Gujarat Themis Biosyn Limited
Pharmaceuticals
match 148
26
99.7
—
-86%
OVERVALUED
INDSWFTLAB
Small
Ind-Swift Laboratories Limited
Pharmaceuticals
match 148
34
51.5
4.0%
-16%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Lasa Supergenerics Limited operates in API, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
53Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 12th percentile of the scored universe and 8th percentile within Pharma. Main check: results consistency is weak at 26/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
17 docs text-extracted · 9 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
12th percentile
overall median 67 · Pharma: 8th pctile, median 70 · Small: 14th pctile, median 66
Evidence depth
Financial-only
17 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
55
watch · leverage and solvency
Discipline
30
weak · capital discipline
Results
26
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸6 years of positive FCF.
Trust risks
- ▸Altman Z is 1.26.
- ▸ROCE is low at -18.2%.
- ▸ROE is low at -19.6%.
- ▸ROCE trend is -26.5%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Lasa Supergenerics Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Bse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.